Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel--a case report.
Cross-resistance is one of the chief obstacles in salvage therapy for refractory breast cancer. Although paclitaxel is one of the most promising drugs, it shows a response rate of 30% at most for patients with breast cancer resistant to doxorubicin, and no effective treatments for tumors refractory to both agents have been reported. We describe a 38-year-old woman with recurrent breast cancer, who was treated successfully with mitomycin-C and vinblastine after doxorubicin-based chemotherapy and paclitaxel failed. The combinations of mitomycin-C and microtubule inhibitors including vinca alkaloids and taxanes may have a potential application to refractory breast cancer.
Sekine
I
I
Division of Oncology/Hematology, National Cancer Center Hospital East, Chiba, Japan.
Sasaki
Y
Y
Fujii
H
H
Ohtsu
T
T
Wakita
H
H
Igarashi
T
T
Itoh
K
K
Abe
K
K
D002293:Adenocarcinoma, Scirrhous / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016685:Mitomycin / Q000627:therapeutic use*; D017239:Paclitaxel / Q000627:therapeutic use; D011859:Radiography; D012008:Recurrence; D017211:Treatment Failure; D014747:Vinblastine / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D016685:Mitomycin; D014747:Vinblastine; D004317:Doxorubicin; D017239:Paclitaxel